All News

2018

September

Media Release / Sep 22, 2018

Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness

Read More
Media Release / Sep 22, 2018

New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD

Read More
Media Release / Sep 21, 2018

Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

Read More
Media Release / Sep 21, 2018

Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe

Read More
Media Release / Sep 21, 2018

Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease

Read More
Media Release / Sep 17, 2018

World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime

Read More
Media Release / Sep 17, 2018

Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals

Read More
Media Release / Sep 13, 2018

Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients

Read More
Media Release / Sep 13, 2018

Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS

Read More
Media Release / Sep 12, 2018

Novartis survey shows psoriasis patients want treatment effect beyond clear skin

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More